Kairos Pharma (KAPA) Investor presentation summary

Mission and strategic focus

• Dedicated to advancing therapies that address cancer drug resistance and immune suppression.

• Focused on reversing resistance in prostate cancer, NSCLC, and other tumor types.

• Seeks partnerships to accelerate clinical development of assets.

Pipeline and clinical programs

• Lead antibody ENV105 targets CD105 to reverse resistance in prostate and EGFR-driven lung cancers.

• ENV105 is in Phase 2 for prostate cancer and Phase 1 for lung cancer, both supported by non-dilutive funding.

• KROS201 immunotherapy cleared IND for glioblastoma; additional preclinical assets target immune evasion and tumor growth.

Clinical trial highlights and efficacy

• ENV105 shows ability to restore sensitivity to hormone therapy in prostate cancer and overcome resistance in lung cancer.

• Phase 2 prostate cancer trial (NCT05534646) reports median PFS of 15.85 months and a 35% mean PSA decrease.

• Preclinical and early clinical data support combination strategies, including with Xofigo for bone metastatic prostate cancer.